Organ-on-Chip Market

The size of global organ-on-chip market in terms of revenue was estimated to be worth $23,285 thousand in 2024 and is poised to reach $631,073 thousand by 2029, growing at a CAGR of 38.6% from 2024 to 2029.  The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Growth in the market can mainly be attributed to the increasing government initiatives to reduce drug testing on animal models. Additionally, factors such as advancements in biofabrication technologies and greater acceptance of organ-on-chip technology by pharma and biotechnology companies also contributes to the growth of this market. However, technical complexities of the organ-on-chip models along with low throughput of current organ-on-chip technology pose challenge for the market growth to a certain extent.

Attractive Opportunities in the Organ-on-chip market

To know about the assumptions considered for the study, Request for Free Sample Report

Organ-on-chip Market Dynamics

Driver: Increasing demand for animal free testing and growing government and private institution funding

Organ-on-chip technology is being developed as a potential substitute to animal drug testing. Often drugs in the final stages of pre clinical trials fail due to differences in animal and human physiology and drug metabolism. This high attrition of potential drug candidates and ethical concerns regarding use of animal for drug testing has lead to development of organ-on-chip technology reduce reliance on animals and to improve drug toxicity testing efficacy. Use of animals for testing of cosmetic drugs is banned in Europe since 2013. In 2023, the US FDA passed Modernization Act 2.0 to reduce animal drug testing and rely on alternative drug testing methods such as organ-on-chips.

Governments and private institutes have shown their interest in the novel organ-on-chip technology. Many government institutions have collaborated with organ-on-chip companies to test the efficacy of the technology as a potential method for future drug discovery and development. For instance, CN Bio Innovation Ltd (UK) collaborated with US Food and Drug Administration (FDA) to improve estimation of drug bioavalibility using muti-organ microphysiological systems. In 2023, MIMETAS B.V. (Netherlands) extended its collaboration with Astellas Pharma Inc. (US) to develop novel cancer treatments for cancer using tumor models from Mimetas.

Thus, this is a major factor driving the growth of the organ-on-chip market during the forecast period.

Restraint: Application of organ-on-chip technology limited to pre clinical trials

Transitioning Organ-on-Chip (OOC) technology to the clinical phase of drug development faces several restrictions such as a limited access to renewable cell sources impacting model reliability, ethical concerns regarding specific cell types like induced pluripotent stem cells (iPSCs), and challenges in accurately representing the complexity of human organs during biological scaling. The low throughput of current OOC technology affect the scalability and efficiency of the model, impeding its integration into clinical research. To address these limitations, the implementation of parallelization and automation in OOC systems, known as High Throughput OOC (HT-OOC) technology, offers a promising solution for advancing drug development beyond preclinical stages, facilitating comprehensive testing of large compound libraries to identify relevant drugs for disease pathogenesis.

Opportunity: Development of multi-organ-on-chip systems

Muti-organ-on-chip systems are developed the functions of multiple organs and inter-organ communications enabling study of drug responses and evaluate drug toxicity for various organs simultaneously. Multi-organ chips (MOCs) are used for safety assessments in the cosmetic and food industries, providing a animal free and efficient compound testing methods. In cosmetics, miniaturized versions of human skin, eyes, and relevant organs, allow for safety evaluations of ingredients and finished products without animal testing. MOCs can be developed with individual specific cells allowing companies to assess interaction of specific compounds with unique skin biology. MOCs incorporating digestive organs allow evaluation of nutrients to develop personalized and nutritious food products. These chips also offer a alternative approach to toxicity testing, replacing traditional animal models.

Challenge: Lack of standardization and low throughput of current organ-on-chip technology

The Organ-on-Chip (OOC) technology is a relatively new and complex technology and therefore faces challenges primarily due to a lack of standardization and low throughput. Standardization is crucial for ensuring consistency and reliability in OOC systems, promoting comparability across different platforms. However, the absence of agreed-upon regulations for reporting experiment findings slow down progress. Additionally, limited scalability and low throughput are also major challenges, restricting large-scale screening studies and increasing costs, making accessibility a concern for smaller research groups and startups. Efforts are underway to address these challenges by developing advanced OOC technology, focusing on designing chips with multiple compartments and integrating automated handling systems.

Organ-on-chip Market Ecosystem

Prominent companies in the market includes companies operating in the market for several years and possess diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in the organ-on-chip market include Emulate, Inc. (US), MIMETAS B.V. (Netherlands), TissUse GmBH (Germany), Netri SAS (France), Insphero (Switzerland), Axosim (US), Obatala Sciences (US), SynVivo, Inc. (US), Nortis, Inc. (US), among others.

The organ-based model accounted for the largest share of the model type segment in overall organ-on-chip industry in 2023.

On the basis of model type, the organ-on-chip market is segmented organ-based model and disease-based model. In 2023, the organ-based model segment accounted for the largest share of the market owing to a high drug development cost and limited efficacy of animal models for drug toxicity studies. Growing interest of pharma and biotechnology companies towards a animal free drug testing approach also supports the growth of this segment.

The liver-on-chip segment dominates the organ type segment in overall organ-on-chip industry in 2023.

On the basis of organ type, the organ-on-chip market is segmented into liver, kidney, lung, heart, intestine and other organs. Liver-on-chip accounted for the largest share of the market owing to factors such as high attrition of potential drug candidates due to human-hepatocytic drug toxicity which is not detectable in animal and 2D cell cultures. Liver-on-chip models allow mimicking of human liver functions and provide more efficient drug delivery and development opportunities.

North America was the largest market for overall organ-on-chip industry in 2023 and also during the forecast period.

Geographically, the organ-on-chip market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The market was dominated by North America in 2023 and this dominance is anticipated to continue throughout the forecast period between 2023 and 2029. The market for organ-on-chip is expanding in the North America region as a result of factors like availability of government and private sector funding and developed organ-on-chip infrastructure.

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the organ-on-chip market are Emulate, Inc. (US), SynVivo, Inc. (US), Nortis, Inc. (US), MIMETAS B.V. (Netherlands), TissUse GmBH (Germany), Netri (France), Insphero (Switzerland), Axosim (US), Obatala Sciences (US) among others.

Scope of the Organ-on-Chip Industry

This report categorizes the Organ-on-chip Market to forecast revenue and analyze trends in each of the following submarkets:

By Model Type

• Organ-based model
• Disease-based model

By Organ Type

• Liver
• Intestine
• Kidney
• Lung
• Heart
• Other organ

By Product and Service

• Products
  • Instruments
  • Consumables & Accessories
  • Software
• Services
  • Custom Services
  • Standard Services

By Application

• Toxicology research
• Drug discovery
• Physiological model development
• Stem cell research
• Tissue regeneration and regenerative medicines

By Purpose

• Therapeutic purpose
• Research purpose

By End User

• Pharmaceutical and biotechnology companies
• Cosmetics industry
• Academic and research institutes
• Other end user

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa

Recent Developments of Organ-on-Chip Industry:

• In September 2023, CN Bio Innovations Ltd (UK) and LifeNet Health LifeSciences (US) partnered to provide validated human cells for CN Bio's Organ-on-a-Chip systems.  
• In June 2023 TissUse GmbH (Germany) and PMI (US) entered a collaborative agreement to leverage PMI's InHALES technology along with TissUse's Multi-Organ-Chip (MOC) platform. 

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst